Linked Life Data

19078970

Source:http://linkedlifedata.com/resource/pubmed/id/19078970

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
2009-1-12
pubmed:abstractText
The sexuality and the management of benign prostatic hyperplasia (BPH) with alfuzosin (SAMBA) trial evaluated the effect of alfuzosin on sexual function in men treated for BPH using two sexual function scales: male sexual health questionnaire (MSHQ) and international index of erectile function (IIEF-15). A total of 148 patients with BPH were treated with alfuzosin for 24 weeks. The patients were followed at baseline, 4, 12 and 24 weeks after medication with alfuzosin. MSHQ was collected at every visit, whereas Q(max), IPSS and IIEF-15 were checked at baseline and end point. At the end point, Q(max) (+4.7 ml s(-1), P<0.01) and IPSS (-5.3, P<0.01) had improved significantly. Alfuzosin also significantly improved the total MSHQ (19.2%, 79.1-94.3, P<0.01) and the MSHQ ejaculatory scores (26.0%, 22.3-28.1, P=<0.01) versus baseline. Alfuzosin for the treatment of patients with BPH is effective in improving sexual function, as well as lower urinary tract symptoms (LUTSs) and quality of life, and is well tolerated.
pubmed:commentsCorrections
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
1476-5489
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
21
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
68-73
pubmed:dateRevised
2009-7-15
pubmed:meshHeading
pubmed:articleTitle
Sexuality and the management of BPH with alfuzosin (SAMBA) trial.
pubmed:affiliation
Department of Urology, Yongdong Severance Hospital, Yonsei University Health System, Seoul, Korea. chung646@yuhs.ac
pubmed:publicationType
Journal Article, Clinical Trial, Research Support, Non-U.S. Gov't